Classification of acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Diagnostics

Background:

• The World Health Organization (WHO) classification of tumors is crucial for standardizing hematologic malignancy diagnoses.
• Recent advancements in high-throughput sequencing and gene expression profiling have significantly impacted the understanding of hematologic malignancies.

Purpose of the Study:

• To review the current WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, focusing on the 2017 revision.
• To highlight key changes in the classification of acute myeloid leukemia (AML) and related precursor neoplasms.
• To emphasize the diagnostic implications of the updated WHO classification for AML.

Main Methods:

• Literature review of the 2017 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.
• Analysis of high-throughput sequencing and gene expression data relevant to hematologic malignancies.
• Synthesis of information regarding diagnostic criteria for AML and precursor neoplasms.

Main Results:

• The 2017 WHO classification integrates novel molecular and genetic findings into the diagnosis of hematologic neoplasms.
• Specific changes in the classification of acute myeloid leukemia (AML) and related precursor neoplasms are identified.
• The revised criteria provide a more refined approach to AML diagnosis.

Conclusions:

• The 2017 WHO classification represents a significant update based on molecular data, improving diagnostic accuracy for AML.
• Understanding these revisions is essential for clinicians and researchers involved in hematologic oncology.
• The classification facilitates consistent diagnosis and communication in the field of hematologic malignancies.